The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. / Deurell, Maria; Weischer, Merete; Pagsberg, Anne Katrine; Labianca, Jette.

I: Nordic Journal of Psychiatry, Bind 62, Nr. 6, 01.01.2008, s. 472-80.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Deurell, M, Weischer, M, Pagsberg, AK & Labianca, J 2008, 'The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey', Nordic Journal of Psychiatry, bind 62, nr. 6, s. 472-80. https://doi.org/10.1080/08039480801985096, https://doi.org/10.1080/08039480801985096

APA

Deurell, M., Weischer, M., Pagsberg, A. K., & Labianca, J. (2008). The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. Nordic Journal of Psychiatry, 62(6), 472-80. https://doi.org/10.1080/08039480801985096, https://doi.org/10.1080/08039480801985096

Vancouver

Deurell M, Weischer M, Pagsberg AK, Labianca J. The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. Nordic Journal of Psychiatry. 2008 jan. 1;62(6):472-80. https://doi.org/10.1080/08039480801985096, https://doi.org/10.1080/08039480801985096

Author

Deurell, Maria ; Weischer, Merete ; Pagsberg, Anne Katrine ; Labianca, Jette. / The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. I: Nordic Journal of Psychiatry. 2008 ; Bind 62, Nr. 6. s. 472-80.

Bibtex

@article{40b08670f82211ddb219000ea68e967b,
title = "The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey",
abstract = "The number of children and adolescents with psychiatric disorders being treated with antipsychotic medication is increasing significantly; however, only a limited evidence-base is available on this topic, especially when children are concerned. This study reports and discusses the use of antipsychotic medication in children and adolescents below 19 years of age in Denmark. A national cross-sectional survey registered the use of antipsychotic drugs on a given date. A questionnaire was sent to all child and adolescent psychiatric departments and all consultants in child and adolescent psychiatry throughout the country. All children and adolescents, aged 0-18 years, registered in treatment with antipsychotic medication, were included. Sixty-seven per cent of clinics and 63% of consultants participated. The total number of subjects registered in examination or treatment in the participating units was 3854. Antipsychotic medication was used in n=244 (6.4%) of these cases. Eighty-eight patients received additional medication, of which 24% received antidepressants, 8% sedative medication and 4% psychostimulants. The age of the patients was 4-18 years, and 63% was male. The most frequent diagnoses for patients in antipsychotic treatment were: schizophrenia, schizotypal disorder, autism spectrum disorders and personality disorders. Monotherapy was used in 87% of cases. Sixty-four per cent of patients treated with antipsychotics, received a second-generation antipsychotic as the main treatment. All 244 patients received one or more additional treatment modalities other than medication. Antipsychotic medication has a definite role in the treatment of children and adolescents with psychiatric disorders. Second-generation antipsychotics used as monotherapy prevail.",
author = "Maria Deurell and Merete Weischer and Pagsberg, {Anne Katrine} and Jette Labianca",
year = "2008",
month = jan,
day = "1",
doi = "10.1080/08039480801985096",
language = "English",
volume = "62",
pages = "472--80",
journal = "Nordisk Psykiatrisk Tidsskrift",
issn = "0803-9496",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey

AU - Deurell, Maria

AU - Weischer, Merete

AU - Pagsberg, Anne Katrine

AU - Labianca, Jette

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The number of children and adolescents with psychiatric disorders being treated with antipsychotic medication is increasing significantly; however, only a limited evidence-base is available on this topic, especially when children are concerned. This study reports and discusses the use of antipsychotic medication in children and adolescents below 19 years of age in Denmark. A national cross-sectional survey registered the use of antipsychotic drugs on a given date. A questionnaire was sent to all child and adolescent psychiatric departments and all consultants in child and adolescent psychiatry throughout the country. All children and adolescents, aged 0-18 years, registered in treatment with antipsychotic medication, were included. Sixty-seven per cent of clinics and 63% of consultants participated. The total number of subjects registered in examination or treatment in the participating units was 3854. Antipsychotic medication was used in n=244 (6.4%) of these cases. Eighty-eight patients received additional medication, of which 24% received antidepressants, 8% sedative medication and 4% psychostimulants. The age of the patients was 4-18 years, and 63% was male. The most frequent diagnoses for patients in antipsychotic treatment were: schizophrenia, schizotypal disorder, autism spectrum disorders and personality disorders. Monotherapy was used in 87% of cases. Sixty-four per cent of patients treated with antipsychotics, received a second-generation antipsychotic as the main treatment. All 244 patients received one or more additional treatment modalities other than medication. Antipsychotic medication has a definite role in the treatment of children and adolescents with psychiatric disorders. Second-generation antipsychotics used as monotherapy prevail.

AB - The number of children and adolescents with psychiatric disorders being treated with antipsychotic medication is increasing significantly; however, only a limited evidence-base is available on this topic, especially when children are concerned. This study reports and discusses the use of antipsychotic medication in children and adolescents below 19 years of age in Denmark. A national cross-sectional survey registered the use of antipsychotic drugs on a given date. A questionnaire was sent to all child and adolescent psychiatric departments and all consultants in child and adolescent psychiatry throughout the country. All children and adolescents, aged 0-18 years, registered in treatment with antipsychotic medication, were included. Sixty-seven per cent of clinics and 63% of consultants participated. The total number of subjects registered in examination or treatment in the participating units was 3854. Antipsychotic medication was used in n=244 (6.4%) of these cases. Eighty-eight patients received additional medication, of which 24% received antidepressants, 8% sedative medication and 4% psychostimulants. The age of the patients was 4-18 years, and 63% was male. The most frequent diagnoses for patients in antipsychotic treatment were: schizophrenia, schizotypal disorder, autism spectrum disorders and personality disorders. Monotherapy was used in 87% of cases. Sixty-four per cent of patients treated with antipsychotics, received a second-generation antipsychotic as the main treatment. All 244 patients received one or more additional treatment modalities other than medication. Antipsychotic medication has a definite role in the treatment of children and adolescents with psychiatric disorders. Second-generation antipsychotics used as monotherapy prevail.

U2 - 10.1080/08039480801985096

DO - 10.1080/08039480801985096

M3 - Journal article

C2 - 18841508

VL - 62

SP - 472

EP - 480

JO - Nordisk Psykiatrisk Tidsskrift

JF - Nordisk Psykiatrisk Tidsskrift

SN - 0803-9496

IS - 6

ER -

ID: 10451157